These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29336436)

  • 1. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Molinero G; Huerín M; Nogueira JP
    High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):263-272. PubMed ID: 31313082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel HDL-based therapeutic agents.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.
    Millán J; Pintó X; Muñoz A; Zúñiga M; Rubiés-Prat J; Pallardo LF; Masana L; Mangas A; Hernández-Mijares A; González-Santos P; Ascaso JF; Pedro-Botet J
    Vasc Health Risk Manag; 2009; 5():757-65. PubMed ID: 19774217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence.
    Stauffer ME; Weisenfluh L; Morrison A
    Vasc Health Risk Manag; 2013; 9():671-80. PubMed ID: 24204156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel concepts in HDL pharmacology.
    Remaley AT; Norata GD; Catapano AL
    Cardiovasc Res; 2014 Aug; 103(3):423-8. PubMed ID: 24951539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Bilz S
    Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
    [No Abstract]   [Full Text] [Related]  

  • 12. Would Janus' view on HDL be useful?
    Kasko M; Kasko V; Oravec S
    Bratisl Lek Listy; 2018; 119(4):245-248. PubMed ID: 29663823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive cardiology in adolescents and the elderly: LDL, HDL, and inflammation.
    Lüscher TF
    Eur Heart J; 2019 Nov; 40(43):3503-3506. PubMed ID: 31725892
    [No Abstract]   [Full Text] [Related]  

  • 16. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Verma S; Leiter LA; Mazer CD; Bain SC; Buse J; Marso S; Nauck M; Zinman B; Bosch-Traberg H; Rasmussen S; Michelsen MM; Bhatt DL
    Circulation; 2018 Oct; 138(15):1605-1607. PubMed ID: 30354517
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
    Tuteja S; Rader DJ
    Nat Rev Endocrinol; 2014 Nov; 10(11):646-7. PubMed ID: 25178730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.